Cortifoam

Discontinue if no improvement within 2–3 weeks. Risk of left ventricular free wall rupture after recent MI. May need dietary salt restriction and potassium supplementation. HPA axis suppression; may need to adjust dose based on changes in thyroid status. Avoid use in the presence of systemic fungal infections, cerebral malaria, optic neuritis, or active ocular herpes simplex. May mask signs of infection. Exclude latent or active amebiasis prior to treatment. Latent tuberculosis (TB) or tuberculin reactivity: monitor closely for TB reactivation. If varicella exposure, prophylaxis with varicella zoster immune globulin may be indicated; consider antivirals if varicella develops. If measles exposure, prophylaxis with immunoglobulin may be indicated. Consider referral to an ophthalmologist if blurred vision or other visual disturbances develop. CHF. Hypertension. Peptic ulcer, diverticulitis, fresh intestinal anastomoses, nonspecific ulcerative colitis: increased risk of GI perforation. Avoid use in immediate or early postoperative period after ileorectostomy. Monitor bone growth in pediatric patients and those at increased risk of osteoporosis (eg, postmenopausal women). Disorders of neuromuscular transmission (eg, myasthenia gravis): risk of acute myopathy. Emotional instability or psychotic tendencies may be worsened. Monitor intraocular pressure if treatment is used for >6wks. Renal impairment. Avoid abrupt cessation. Pregnancy. Nursing mothers.